Case Report: Excellent Response to Long-Term Higher Dose Single Olanzapine in a Case of Recurrent Brief Depression

 

 Buy Article Permissions and Reprints

Abbreviations

ACTH

adrenocorticotropic hormone, corticotropin

BPD

borderline personality disorder

DIB

diagnostic interview for borderlines

DSM

Diagnostic and Statistical Manual of Mental Disorders

HDRS-17

Hamilton depression rating scale of 17 items

ICD

international classification of diseases

MD

major depression

OLZ

olanzapine

RBD

recurrent brief depression

SADS-L

the schedule for affective disorders and schizophrenia, lifetime version

T3

triiodothyronine

T4

tetraiodothyronine, thyroxine

TSH

thyroid-stimulating hormone

References

• 1 American Psychiatric Association .Diagnostic and statistical manual of mental disorders. 4th Edition. Washington, DC: American Psychiatric Association 1994
• 2 Angst J, Merinkangas K, Scheidegger P, Wicki W. Recurrent brief depression: a new subtype of affective disorder.  J Affective Disorders. 1990;  19 87-98
  CrossrefPubMedGoogle Scholar
• 3 Angst J, Sellaro R, Merikangas K. Depressive Spectrum Diagnoses.  Comprehensive Psychiatry. 200;  41 39-47
  PubMedGoogle Scholar
• 4 Assion HJ, Jungck C. Off-label prescribing in a German psychiatric hospital.  Pharmacopsychiatry. 2007;  40 30-36
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Earley W, Mitchel M, Marquez E, Kurtz D, Falk D, Taylor CC, Cavazzoni P. Preliminary pharmacokinetics and tolerability of higher dose olanzapine. Presented at the 157th annual meeting of the American Psychiatric Association. New York, NY May 1–6, 2004
• 6 Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia.  Arch Gen Psychiatry. 1978;  35 837-444
  PubMedGoogle Scholar
• 7 Glazer WM. Olanzapine and the new generation of antipsychotic agents: patterns of use.  J Clin Psychiatr. 1997;  58 18-21
  PubMedGoogle Scholar
• 8 Gunderson JG, Kolb JE, Austin V. The diagnostic interview for borderline patients (DIB).  Am J Psychiatr. 1981;  138 896-903
  PubMedGoogle Scholar
• 9 Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics.  Pharmacoepidemiology Drug Safety. 2003;  12 423-424
  CrossrefPubMedGoogle Scholar
• 10 Jackson WC, Manning JS, Connor PD, Deardorff OG. Retrospective study of olanzapine in depressive and anxious states primary care. Primary care companion.  J Clin Psychiatr. 2004;  6 199-202
  PubMedGoogle Scholar
• 11 Jarema M. Atypical antipsychotics in the treatment of mood disorders.  Current Opinion in Psychiatry. 2007;  20 23-29
  PubMedGoogle Scholar
• 12 Karow A, Schnedler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics.  Pharmacopsychiatry. 2006;  39 47-51
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Keck Jr PE, Strakowski SM, MacElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.  J Clin Psychiatr. 2000;  61 4-9
  PubMedGoogle Scholar
• 14 Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety.  J Clinical Psychiatr. 2006;  66 13-21
  PubMedGoogle Scholar
• 15 Pezawas L, Angst J, Kasper S. Recurrent brief depression revisited.  Int Rev Psychiatry. 2005;  17 63-70
  CrossrefPubMedGoogle Scholar
• 16 World Health Organization .The ICD-10 Classification of Mental and BehaviouraI Disorders, Clinical Descriptions and Diagnostic Guidelines. WHO. Geneva 1992

Correspondence

J. M. De la FuenteMD, PhD 

Lannemezan Psychiatric Hospital

Route de Toulouse

65300 Lannemezan

France

Phone: +33/5/6299 55 25

Fax: +33/5/6299 53 05

Email: jdlf@ch-lannemezan.fr